An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Roflumilast (Primary)
- Indications Obesity; Prediabetic state
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 26 Jul 2017 Status changed from recruiting to completed.
- 07 Apr 2017 Planned primary completion date changed from 30 Mar 2017 to 30 Sep 2018.